Expanding at a steady CAGR of 4%, the global hip reconstruction devices market is valued at US$ 8.21 billion in 2023 and is projected to reach US$ 12.15 billion by the year 2033. Hip reconstruction devices are bifurcated into primary hip reconstruction devices, partial hip reconstruction devices, revision hip reconstruction devices, and hip resurfacing devices. Sales of primary hip reconstruction devices are expected to progress at a CAGR of 4.5% during the forecast period.

Primary hip reconstruction is a clinical intervention where a primary joint replacement procedure is carried out on the specific injured joint of the patient. A damaged or worn-out hip joint is replaced using implants made of metal, high-density polyethylene, or ceramic during a primary hip replacement surgery.

Download a Sample Copy of This Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=8249?PJ 

“Increasing Senior Population and Presence of Leading Hip Reconstruction Device Manufacturers”

The United States is currently dominating the North American hip reconstruction devices market. This dominance can be attributed to the factors such as the rising rate of the senior population in the nation, the high prevalence of hip fractures and arthritis, and the presence of well-established healthcare infrastructure and key market players.

Additional factors anticipated to boost market growth include advantageous government healthcare policies and the rising number of research partnerships.

Key Companies Profiled

• B. Braun Melsungen AG
• Corin Group PLC
• DePuy Synthes
• Exactech, Inc.
• MicroPort Scientific Corporation
• Smith & Nephew PLC
• Stryker Corporation
• United Orthopedic Corporation
• Waldemar Link GmbH & Co. KG
• Zimmer Biomet Holdings, Inc.

Competitive Landscape

Global leaders in terms of market revenue are Zimmer Biomet, DePuy Synthes, and Stryker Corporation. Zimmer Biomet holds the largest market share due to increasing sales of its hip implants. On the other side, DePuy Synthes and Stryker are in the top positions as a result of their strong sales forces, superior local supply capabilities, and attention to both organic and inorganic growth strategies.

• The ROSA Hip System for robotically-assisted direct anterior total hip replacement has been approved by the U.S. Food and Drug Administration (FDA), according to a statement issued by Zimmer Biomet Holdings, Inc. in August 2021.

Segmentation of Hip Reconstruction Devices Industry Research

• By Indication :

  • Osteoarthritis

  • Rheumatoid Arthritis

  • Trauma

• By Product :

  • Primary Hip Reconstruction Devices

  • Partial Hip Reconstruction Devices

  • Revision Hip Reconstruction Devices

  • Hip Resurfacing Devices

• By Material :

  • Metal-on-metal

  • Metal-on-polyethylene

  • Ceramic-on-polyethylene

  • Ceramic-on-metal

  • Ceramic-on-ceramic

• By End User :

  • Hospitals

  • Orthopedic Clinics

  • Ambulatory Surgical Centers

• By Region :

  • North America

  • Latin America

  • Europe

  • East Asia

  • South Asia & Oceania

  • MEA